The present invention relates to a pharmaceutical combination comprising paclitaxel, or its pharmaceutically acceptable salt； and at least one cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof, for use in the treatment of triple negative breast cancer (TNBC). The present invention relates to a method for the treatment of breast cancer, particularly triple negative breast cancer, by administration to a patient in need thereof, a therapeutically effective amount of a pharmaceutical combination comprising a cytotoxic antineoplastic agent, paclitaxel, and at least one cyclin dependent kinase (CDK) inhibitor； wherein said combination on administration exhibits synergistic effects.本發明有關一種醫藥組合，該醫藥組合包含紫杉醇或其藥學可接受的鹽類；以及由分子式I化合物（如本文中所描述）表示的至少一細胞週期蛋白依賴型激酶（CDK）抑制劑或其藥學可接受的鹽類，用於治療三重陰性乳癌（TNBC）。本發明有關一種用於治療乳癌的方法，特別是三重陰性乳癌，藉由將醫療有效量的醫藥組合投藥至需要其的病患，該醫藥組合包含細胞毒性抗腫瘤劑（紫杉醇）以及至少一細胞週期蛋白依賴型激酶（CDK）抑制劑；其中所述組合在投藥上展現了協同作用。
